425: Tempus AI Acquires Personalis, Boosts Diagnostics and Data Business

Tempus AI CEO Eric Lefkofsky discusses strong Q2 results, the strategic acquisition of Personalis, and the accelerating demand for AI-driven solutions in biopharma.

Summary

• Tempus AI reported strong second-quarter performance, driven by robust growth in its diagnostic business, particularly comprehensive genomic profiling for solid tumors and liquid biopsies.
• The company's data licensing business also saw significant growth, with approximately $200 million in TCV (Total Contract Value) added in the last quarter, fueled by biopharma's migration to AI solutions.
• Tempus AI announced the acquisition of Personalis, a company with a best-in-class whole genome-based assay, which is expected to significantly increase ASPs (Average Selling Prices) and become a strong financial product within Tempus's platform.
• The acquisition of Personalis is strategically timed, as Personalis was selected as the sequencing partner for the Merck and Moderna V940 melanoma vaccine trial, a program where sequencing is integral to the manufacturing process.
• Tempus AI anticipates substantial revenue and margin benefits from the Personalis acquisition and its role in the V940 trial, with potential for significant uplift in 2027.
• The company's hereditary business is expected to return to mid-teen growth rates by the end of the year, driven by underlying demand and the resolution of temporary growth distortions.
• Tempus AI's data business is experiencing strong demand from biopharma for AI-driven drug discovery, with multiple long-term data licensing deals exceeding $100 million.
• The company highlights its competitive moat in data, built over years of connecting to thousands of hospitals, harmonizing data, and building tools around it, which has resulted in significant traction compared to competitors.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, driven by strong core business performance and strategic acquisitions that enhance future growth prospects.

Positives

• Strong, broad-based performance in the second quarter, with durable unit growth rates in diagnostic business (solid tumor and liquid biopsy).
• Data licensing business grew approximately 36% last quarter, with over $100 million in TCV added for three consecutive quarters, reaching around $200 million last quarter.
• Acquisition of Personalis, possessing a best-in-class whole genome-based assay with high sensitivity and specificity, is expected to significantly increase ASPs.
• Personalis's role as the sequencing partner for the Merck and Moderna V940 melanoma vaccine trial, a program where sequencing is a component of the manufacturing process, presents a significant opportunity.
• Tempus AI won an RFP to handle a significant portion of the revenue and volume associated with the V940 trial approval post-FDA approval.
• The solid tumor assay received FDA approval for tumor-only testing with ADLT pricing, effective January 1, leading to an immediate step-up in pricing from approximately $2,923 to $4,500 for over half of the solid tumor portfolio.
• Expected significant step-up in liquid biopsy pricing from approximately $3,200 to the mid-to-high $7,000 range in the back half of 2027.
• Hereditary business expected to return to mid-teen growth rates by the end of the year, with sustainable long-term growth projected between 12% to 18%.

Negatives

• The difference in revenue projections for the combined entity between Personalis ($758 million in 2030) and Tempus ($333 million) is primarily due to differing assumptions on ASP increases and the pace of regulatory approvals for specific indications.
• The hereditary business experienced fluctuating growth rates, with a period of extreme growth (30-40%) largely due to Invitae's bankruptcy, followed by low-single-digit growth, which is now being lapped.
• The market for genetic counselors, who order hereditary tests, is a bottleneck, limiting the testing of a large number of individuals for whom coverage policies exist.

Risks

• The proposed transaction between Tempus and Personalis is subject to various risks, including the occurrence of any event that could lead to termination of the merger agreement.
• There is a risk that Personalis stockholders may not adopt the merger agreement.
• Governmental and regulatory approvals required for the transaction may be delayed or may impose conditions that could lead to abandonment of the merger.
• The parties may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all.
• Disruption of management time from ongoing business operations due to the proposed transaction.
• Adverse effects on the market price of Tempus or Personalis common stock due to announcements related to the proposed transaction.
• Risk of prior closing market price of Tempus Class A common stock falling below $46.00, giving Personalis the right to terminate the Merger Agreement.
• Potential for unexpected costs or expenses resulting from the proposed transaction and potential litigation relating to it.

Future Outlook

The company anticipates continued strong demand for its diagnostic and data businesses, catalyzed by AI adoption in biopharma. The acquisition of Personalis is expected to significantly enhance revenue and margins, particularly with the integration of its best-in-class assay and its role in the V940 melanoma vaccine trial. Regulatory and pricing upgrades for solid tumor and liquid biopsy assays are projected to drive substantial financial benefits in the coming years. The hereditary business is expected to stabilize and grow at mid-teen rates.

Management Comments

• The core strength of our diagnostic business, in particular around comprehensive genomic profiling and how kind of durable those growth rate, those unit growth rates are, both in terms of solid tumor profiling and liquid biopsy.
• Our data business continues to perform really well. I think our data licensing business grew about 36% or something in the last quarter.
• We have had something like three quarters in a row of more than $100 million of TCV. I think last quarter it was around $200 million of TCV add, meaning our bookings for that quarter, people signing new data licenses were $200 million or whatever.
• We have long thought that Personalis assay was best-in-class, its whole genome based. It has incredible sensitivity and specificity.
• It makes a ton of sense inside our platform. Its a best-in-class assay. The unit growth is really strong. Were already distributing it, so its already a part of our portfolio and they will have ASPs that will rise.
• Tempus unrelated to Personalis will be handling a significant amount of the kind of revenue and volume associated with that approval [V940 trial].
• My best guess is that its quite big [the V940 drug opportunity], both because the performance of this drug, its ability to essentially allow patients that dont respond to immunotherapy to respond is pretty extraordinary.
• Our pricing works identical to AWS. You can license one file from us for a few thousand bucks. So, the only reason these people are entering into long-term contracts is they want access to data and they want discounts.
• Our data is invaluable for understanding synthetic controls, understanding how to design a Phase 2 and which mechanisms of action are driving response.
• I think conservatively, this over the next three to five years grows mid-teens. If we get any of that right, it should have growth rates that are equal to or greater than cancer risks.
• We have just done all that [building the data product]. And if you look at it, everyone whos tried to launch a data business, which is most of our major competitors, if you look at the launch of their data business, its five, six, seven years old, have just had no traction, basically, and we continue to have significant traction.

Industry Context

StockSavvy.ai notes that Tempus AI's strategy aligns with major industry trends, including the increasing adoption of AI in drug discovery and development, the growing importance of comprehensive genomic profiling for personalized medicine, and the critical role of high-quality, de-identified data in advancing healthcare research. The acquisition of Personalis and the company's involvement in the V940 trial highlight the convergence of diagnostics, therapeutics, and data analytics in oncology.

Comparison to Industry Standards

• The data licensing business's growth and multi-billion dollar TCV deals with major biopharma companies (AstraZeneca, BMS, GSK, Merck, BioNtech) indicate a strong market position, comparable to established data providers like AWS in terms of licensing models.
• The projected margins for the MRD space (80% in the next decade) are exceptionally high, potentially exceeding industry norms for diagnostic services, though comparable to some high-margin software or specialized service businesses.
• The company's approach to data monetization, offering tiered access similar to cloud services, is a recognized strategy for scaling data businesses in the life sciences sector.
• The competitive landscape for data includes players like ConcertAI, Caris, Flatiron, and Foundation Medicine, but Tempus AI claims to have significantly outpaced them in traction and growth for rich molecular data.

Legal Proceedings

• Potential litigation relating to the proposed transaction between Tempus and Personalis.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to strong business performance, strategic acquisition, and anticipated revenue/margin growth. The acquisition of Personalis is expected to be accretive.
• Employees: Potential for expanded opportunities within a larger, integrated company. Integration may lead to some restructuring.
• Customers (Biopharma): Access to enhanced diagnostic capabilities and a more comprehensive data platform for AI-driven drug discovery and development.
• Customers (Healthcare Providers): Continued access to advanced genomic profiling and molecular diagnostics, with potential for improved patient outcomes.
• Creditors: The financial health of the combined entity is expected to strengthen, potentially improving creditworthiness.

Next Steps

• Complete the acquisition of Personalis.
• Integrate Personalis's assay and operations into Tempus's platform.
• Execute on the V940 melanoma vaccine trial sequencing and manufacturing integration.
• Implement new ADLT pricing for solid tumor assays effective January 1.
• Anticipate FDA approval and pricing for liquid biopsy in the back half of 2027.
• Continue to expand data licensing agreements with biopharma companies.
• Address the bottleneck in genetic counselor availability to unlock latent demand in hereditary testing.

Key Dates

Recommendation

The filing details exceptionally strong core business performance, a highly strategic and accretive acquisition (Personalis), significant upcoming pricing power from regulatory approvals (ADLT pricing, liquid biopsy), and a clear acceleration in the high-growth data licensing business driven by AI. The company's competitive moat in data and diagnostics, coupled with a robust pipeline of future revenue drivers, presents a compelling investment case.

Keywords

genomic profiling, liquid biopsy, data licensing, AI drug discovery, Personalis acquisition, oncology, molecular profiling, clinical trials